Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto after TAVI in symptomatic aortic stenosis
jRCT1031220344Active, not recruiting
- Sponsor
- Chiba University Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sacubitril + valsartan in aortic stenosis (AS) and heart failure (HF) (2 arms), sponsored by Chiba University Hospital. Primary endpoint: NT-proBNP value at 6 months follow-up. Started Oct 2022; status: active, not recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
aortic stenosis (AS)heart failure (HF)
Beyond the preview
Go deeper on jRCT1031220344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220344.